The Company has an innovative and broad expertise on product candidates that it believes can overcome the deficiencies of current treatment options for a variety of cardiovascular and inflammatory diseases. We have several drugs in various stages of clinical investigation. Our lead drug candidate uses our proprietary formulation of the repositionning cardiovascular compound for the treatment of bowel pain and inflammation.

Current areas of therapeutic focus are: atrial fibrillation, post myocardial infarction remodelling, thrombotic diseases, bowel pain and crohn diseases